NCT02779140View on ClinicalTrials.gov

Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Botulism
Interventions
BIOLOGICAL

NTM-1632

Monoclonal antibody mixture of XB10, XB18, and XB23

OTHER

Placebo

Placebo

Trial Locations (1)

27704

Duke Human Vaccine Institute - Duke Clinical Vaccine Unit, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02779140 - Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 | Biotech Hunter | Biotech Hunter